Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Csl Behring LLC is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners, indicating a diversified prosecution environment where each pending matter is reviewed by a different individual. This distribution requires a broad strategy to address the varying perspectives of multiple USPTO officials.
The portfolio spans multiple art units, matching the number of examiners and pending actions. This one-to-one ratio between actions, examiners, and art units suggests that each matter is isolated within its own administrative silo. The busiest examiner, KO, JASON Y, is responsible for 1 pending office action, reflecting a perfectly even workload distribution where no single examiner holds more than one action.
With the pending actions spread across many distinct art units, the company must navigate the specific guidelines of multiple specialized groups. The presence of many distinct examiners for the pending actions increases the variability of the prosecution process. Practitioners should prepare for unique examiner styles rather than a centralized negotiation strategy for the 4 pending matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KO, JASON Y | 1 | 75.7% | +16.7% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17353440 | NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS | MCLEOD, AFRICA MHAIRIE | 42d overdue |
| 18847807 | APPARATUS AND METHOD FOR CLEANING FILTER PLATES | KO, JASON Y | — |
| 18078977 | DONOR T-CELLS WITH KILL SWITCH | ZHU, JIANJIAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17353440 | NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS | MCLEOD, AFRICA MHAIRIE | 42d overdue |
| 18513964 | Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation | BEANE, RANDALL L | 70d |
| 18847807 | APPARATUS AND METHOD FOR CLEANING FILTER PLATES | KO, JASON Y | — |
| 18078977 | DONOR T-CELLS WITH KILL SWITCH | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1711 | 1 |
| 1654 | 1 |
| 1631 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847807 | APPARATUS AND METHOD FOR CLEANING FILTER PLATES | KO, JASON Y | 1711 | §102§103 | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18513964 | Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 70d | Pending | Nov 20, 2023 |
| 18078977 | DONOR T-CELLS WITH KILL SWITCH | ZHU, JIANJIAN | 1631 | §103§112Other | Non-Final OA | — | Pending | Dec 11, 2022 |
| 17353440 | NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS | MCLEOD, AFRICA MHAIRIE | 1635 | §101§102 | Non-Final OA | 42d overdue | Pending | Jun 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCsl Behring LLC has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Jason Y Ko has the most, with 1 of Csl Behring LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
